- Chart review is expected to collect real-world data on patients with respiratory complications associated with COVID-19 who received INOmax® (nitric oxide) gas, for inhalation in a hospital setting ...

- Company ends Phase 4 observational registry early as data achieved statistical significance for non-inferiority in premature neonates compared to term and near-term neonates at planned interim ...

STAINES-UPON-THAMES, United Kingdom, Nov. 8, 2018 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, today announced it has received the ...

Mallinckrodt announced that the phase 4 observational registry study evaluating INOmax® (nitric oxide) gas, for inhalation, in preterm neonates with pulmonary hypertension was stopped early due to ...

Type: Inhaled nitric oxide (iNO) indicated in the U.S. for term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension. Status: Mallinckrodt said April 30 it ...

STAINES-UPON-THAMES, United Kingdom, May 4, 2020 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today announced that its observational registry comparing the safety ...